Related Experiment Video
Updated: Sep 27, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Predicting Glycaemia in Type 1 Diabetes Patients: Experiments in Feature Engineering and Data Imputation
Jouhyun Jeon1, Peter J Leimbigler1, Gaurav Baruah1
1Klick Inc., 175 Bloor Street East, Toronto, Ontario Canada.
Abstract:
Patients with type 1 diabetes manually regulate blood glucose concentration by adjusting insulin dosage in response to factors such as carbohydrate intake and exercise intensity. Automated near-term prediction of blood glucose concentration is essential to prevent hyper- and hypoglycaemic events in type 1 diabetes patients and to improve control of blood glucose levels by physicians and patients. The imperfect nature of patient monitoring introduces missing values into all variables that play important roles to predict blood glucose level, necessitating data imputation. In this paper, we investigated the importance of variables and explored various feature engineering methods to predict blood glucose level. Next, we extended our work by developing a new empirical imputation method and investigating the predictive accuracy achieved under different methods to impute missing data. Also, we examined the influence of past signal values on the prediction of blood glucose levels. We reported the relative performance of predictive models in different testing scenarios and different imputation methods. Finally, we found an optimal combination of data imputation methods and built an ensemble model for the reliable prediction of blood glucose levels on a 30-minute horizon.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Dipeptidyl Peptidase 4 Inhibitors
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

